Intrahepatic Cholangiocarcinoma
Showing 1 - 25 of 768
Intrahepatic Cholangiocarcinoma Trial in Padova (Liver transplantation)
Not yet recruiting
- Intrahepatic Cholangiocarcinoma
- Liver transplantation
-
Padova, ItalyAzienda Ospedale Università di Padova
Oct 25, 2023
Locally Advanced Non-metastatic Intrahepatic Cholangiocarcinoma, Determine Efficacy of Liver Transplantation After Neoadjuvant
Not yet recruiting
- Locally Advanced Non-metastatic Intrahepatic Cholangiocarcinoma
- Determine Efficacy of Liver Transplantation After Neoadjuvant Systemic Therapy in Patients With Locally Advanced Non-metastatic Intrahepatic Cholangiocarcinoma
- Liver Transplant
-
Newark, New Jersey
- +1 more
Nov 14, 2023
Cholangiocarcinoma Trial in Houston (Pembrolizumab, Gemcitabine, Cisplatin)
Not yet recruiting
- Cholangiocarcinoma
- Pembrolizumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 21, 2023
Locally Advanced Intrahepatic Cholangiocarcinoma, Oligometastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic
Not yet recruiting
- Locally Advanced Intrahepatic Cholangiocarcinoma
- +4 more
- Angiography
- +8 more
-
Jacksonville, FloridaMayo Clinic in Florida
Sep 22, 2023
Carcinoma, Intrahepatic Cholangiocarcinoma, Digestive System Tumors Trial in Guangzhou (Pemigatinib, PD-1 Inhibitors)
Recruiting
- Carcinoma
- +4 more
- Pemigatinib
- PD-1 Inhibitors
-
Guangzhou, Guangdong, ChinaLei Zhang
Jun 21, 2023
Predict Efficacy of GC in Treatment of Intrahepatic
Not yet recruiting
- Organoids
- Intrahepatic Cholangiocarcinoma
- gemcitabine + cisplatin
- (no location specified)
Nov 30, 2022
Unresectable Intrahepatic Cholangiocarcinoma Trial (Camrelizumab, Gemcitabine Injection, Cisplatin injection)
Not yet recruiting
- Unresectable Intrahepatic Cholangiocarcinoma
- Camrelizumab
- +4 more
- (no location specified)
Feb 17, 2023
Borderline Resectable Carcinoma, Biliary Tract Cancer Trial in Washington (Durvalumab, Tremelimumab, Gemcitabine)
Not yet recruiting
- Borderline Resectable Carcinoma
- Biliary Tract Cancer
- Durvalumab
- +4 more
-
Washington, District of ColumbiaLombardi Comprehensive Cancer Center, Georgetown University
Aug 24, 2023
Unresectable Intrahepatic Cholangiocarcinoma Trial in Baltimore (Durvalumab, SNDX-6352)
Active, not recruiting
- Unresectable Intrahepatic Cholangiocarcinoma
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center
Jan 10, 2023
Durvalumab, Intrahepatic Cholangiocarcinoma, Gemcis Trial in Tianjin (Durvalumab, Surgery, Gemcitabine)
Recruiting
- Durvalumab
- +2 more
- Durvalumab
- +3 more
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Jan 3, 2023
Locally Advanced Intrahepatic Cholangiocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Stage III Intrahepatic
Recruiting
- Locally Advanced Intrahepatic Cholangiocarcinoma
- +5 more
- Bintrafusp Alfa
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Aug 18, 2022
Intrahepatic Cholangiocarcinoma Trial in Shanghai (Cadonilimab+Gem/Cis)
Active, not recruiting
- Intrahepatic Cholangiocarcinoma
-
Shanghai, Shanghai, ChinaEastern hepatobilliary surgery hospital
Mar 22, 2023
Intrahepatic Cholangiocarcinoma Trial in Tianjin (Regorafenib and HAIC, FOLFOX)
Not yet recruiting
- Intrahepatic Cholangiocarcinoma
- Regorafenib and HAIC
- FOLFOX
-
Tianjin, ChinaTianjin Medical University Cancer Institute and Hospital
Sep 7, 2022
Intrahepatic Cholangiocarcinoma Trial in Oslo (Liver Transplant)
Recruiting
- Intrahepatic Cholangiocarcinoma
- Liver Transplant
-
Oslo, NorwayOslo University Hospital
Oct 4, 2022
Metastatic Colorectal Cancer (Mcrc), Intrahepatic Cholangiocarcinoma (Icc), Colorectal Cancer Trial run by the National Cancer
Recruiting
- Metastatic Colorectal Cancer (Mcrc)
- +7 more
- Floxuridine
- +8 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 23, 2023
Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable Trial in Boston (Gemcitabine, Cisplatin, Durvalumab)
Not yet recruiting
- Bile Duct Cancer
- +4 more
- Gemcitabine
- +3 more
-
Boston, MassachusettsBeth Israel Deaconess Medical Center
Jan 23, 2023
Resectable Cholangiocarcinoma, Stage IB Intrahepatic Cholangiocarcinoma AJCC v8, Stage II Intrahepatic Cholangiocarcinoma AJCC
Active, not recruiting
- Resectable Cholangiocarcinoma
- +5 more
- Cisplatin
- +2 more
-
Atlanta, Georgia
- +6 more
Oct 5, 2022
Intrahepatic Cholangiocarcinoma Trial in GuangZhou (HAIC Combined with Tislelizumab and Apatinib)
Recruiting
- Intrahepatic Cholangiocarcinoma
- HAIC Combined with Tislelizumab and Apatinib
-
GuangZhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Aug 4, 2022
Advanced Intrahepatic Cholangiocarcinoma Trial in Shanghai (Cryoablation, Sintilimab, Lenvatinib)
Recruiting
- Advanced Intrahepatic Cholangiocarcinoma
- Cryoablation
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Apr 28, 2023
/or PD-1 Inhibitors for Unresectable Intrahepatic
Completed
- Intrahepatic Cholangiocarcinoma
- hepatic arterial infusion chemotherapy (HAIC) of oxaliplatin, fluorouracil, and leucovorin (FOLFOX)
-
GuangZhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Aug 7, 2022
Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer Trial in Tianjin
Recruiting
- Potentially Resectable Locally Advanced Intrahepatic Cholangiocarcinoma and Gallbladder Cancer
-
Tianjin, Tianjin, ChinaTianjin Medical University Cancer Institute & Hospital
Nov 16, 2022
Liver and Intrahepatic Bile Duct Carcinoma, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Intrahepatic
Recruiting
- Liver and Intrahepatic Bile Duct Carcinoma
- +5 more
- Dexamethasone
- +6 more
-
Portland, OregonOHSU Knight Cancer Institute
Oct 11, 2022
Advanced Intrahepatic Cholangiocarcinoma Trial (Pemigatinib)
Not yet recruiting
- Advanced Intrahepatic Cholangiocarcinoma
- (no location specified)
Sep 30, 2022
Intrahepatic Cholangiocarcinoma Trial in Guangzhou (HAIC Combined with Tislelizumab and Apatinib)
Recruiting
- Intrahepatic Cholangiocarcinoma
- HAIC Combined with Tislelizumab and Apatinib
-
Guangzhou, Guangdong, ChinaSun Yat-Sen University Cancer Center
May 28, 2022